ATRIUM THERAPEUTICS, INC.
RNALoading price...
Overview
Previous Close11.46
Open11.44
Ask14.41
Bid8.10
Day's Range11.20 - 11.54
52 Week Range11.13 - 16.77
PE Ratio(TTM)--
Market Cap194.15M
Volume114.44k
Avg. Volume201.59k
12 Months Earnings-85.87M
12 Months Revenue36.68M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Operating Revenue | 36.68M | 18.62M | 10.90M | 9.76M |
| Operating Expenses | 123.32M | 95.43M | 24.11M | 16.15M |
| Profit after Tax (Net Income) | -85.87M | -76.68M | -25.12M | -6.38M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: San Diego, United States
Website: https://atriumtherapeutics.com
President, CEO & Director: Ms. Kathleen P. Gallagher
About Company:
Atrium Therapeutics, Inc., a biopharmaceutical company, focuses on delivering ribonucleic acid (RNA) therapeutics to the heart to transform the care for people living with cardiomyopathies. The company's development stage product candidates include ATR 1072, a siRNA-based therapy targeting PRKAG2 for the treatment of PRKAG2 syndrome; and ATR 1086, a siRNA-based therapy targeting PLN for the treatment of PLN cardiomyopathy. It also focuses on pipeline to treat a range of genetic and cardiac diseases. It has a research collaboration and license agreement with Bristol-Myers Squibb Company and Eli Lilly and Company. The company was incorporated in 2025 and is headquartered in San Diego, California.